

Vanda Markovic-Pekovic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1899036/publications.pdf>

Version: 2024-02-01

43
papers

1,428
citations

279798

23
h-index

361022

35
g-index

43
all docs

43
docs citations

43
times ranked

1276
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress on the national action plan of Pakistan on antimicrobial resistance (AMR): a narrative review and the implications. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 71-93.	4.4	38
2	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <i>Scripta Medica</i> , 2022, 53, 29-35.	0.1	0
3	COVID-19, health care and self-medication issues in resource-limited settings: Findings and implications based on experiences in Ghana. <i>Advances in Human Biology</i> , 2021, 11, 224.	0.2	6
4	Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications. <i>Medicine Access Point of Care</i> , 2021, 5, 239920262110276.	1.0	7
5	Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 527-540.	1.4	48
6	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. <i>Life</i> , 2021, 11, 528.	2.4	95
7	The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. <i>Frontiers in Public Health</i> , 2021, 9, 671961.	2.7	22
8	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1019-1052.	1.4	30
9	Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. <i>BioMed Research International</i> , 2021, 2021, 1-16.	1.9	7
10	Regulation of the apothecary activity in Bosnia and Herzegovina over the Austro-Hungarian period. <i>Medicinski Glasnik</i> , 2021, 18, 343-351.	0.4	0
11	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. <i>Current Medical Research and Opinion</i> , 2020, 36, 301-327.	1.9	111
12	Fixed dose drug combinations “ are they pharmaco-economically sound? Findings and implications especially for lower- and middle-income countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 1-26.	1.4	47
13	The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures. <i>Frontiers in Pharmacology</i> , 2020, 11, 591134.	3.5	44
14	The first modern pharmacy in Banja Luka: The Brammer family, three generations of pharmacists. <i>Scripta Medica</i> , 2020, 51, 284-291.	0.1	1
15	Proposal for a regulation on health technology assessment in Europe “ opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 251-261.	1.4	31
16	Pricing of oral generic cancer medicines in 25 European countries; findings and implications. <i>GaBI Journal</i> , 2019, 8, 49-70.	0.3	31
17	The characteristics of the outpatient utilisation of medicines in the Republic of Srpska in the period 2009-2017. <i>Scripta Medica</i> , 2019, 50, 167-176.	0.1	0
18	Are pharmacists’s good knowledge and awareness on antibiotics taken for granted? The situation in Albania and future implications across countries. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 13, 240-245.	2.2	53

#	ARTICLE	IF	CITATIONS
19	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. <i>Frontiers in Public Health</i> , 2018, 6, 328.	2.7	102
20	Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. <i>Frontiers in Pharmacology</i> , 2018, 8, 942.	3.5	70
21	Recent Initiatives in the Republic of Srpska to Enhance Appropriate Use of Antibiotics in Ambulatory Care; Their Influence and Implications. <i>Frontiers in Pharmacology</i> , 2018, 9, 442.	3.5	33
22	The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications. <i>Pharmacoeconomics</i> , 2017, 35, 1271-1285.	3.3	94
23	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. <i>Frontiers in Pharmacology</i> , 2017, 8, 497.	3.5	34
24	Initiatives to reduce nonprescription sales and dispensing of antibiotics: Findings and implications. <i>Journal of Research in Pharmacy Practice</i> , 2017, 6, 120.	0.7	70
25	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. <i>Frontiers in Pharmacology</i> , 2016, 7, 197.	3.5	26
26	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. <i>Frontiers in Pharmacology</i> , 2016, 7, 305.	3.5	48
27	Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 609-618.	1.4	15
28	Long-term drug use and polypharmacy among the elderly population in the Republic of Srpska, Bosnia and Herzegovina. <i>Vojnosanitetski Pregled</i> , 2016, 73, 435-441.	0.2	1
29	Vanbolnička potrošnja antibiotika u Republici Srpskoj u periodu od 2009. do 2014. Godine. <i>Scripta Medica</i> , 2016, 47, 48-53.	0.1	0
30	Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future. <i>GaBI Journal</i> , 2015, 4, 125-135.	0.3	10
31	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. <i>Frontiers in Pharmacology</i> , 2014, 5, 109.	3.5	44
32	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. <i>Frontiers in Pharmacology</i> , 2014, 5, 106.	3.5	107
33	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. <i>Frontiers in Pharmacology</i> , 2013, 4, 39.	3.5	75
34	Outpatient utilization of systemic antibiotics in the Republic of Srpska. <i>Scripta Medica</i> , 2013, 44, 8-13.	0.1	0
35	Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 661-671.	1.4	29
36	Self-medication with antibiotics in the Republic of Srpska community pharmacies: pharmacy staff behavior. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 1130-1133.	1.9	41

#	ARTICLE	IF	CITATIONS
37	Essential to increase the use of generics in Europe to maintain comprehensive health care?. <i>Farmaeconomia E Percorsi Terapeutici</i> , 2012, 13, 5-20.	0.1	24
38	Outpatient utilization of drugs acting on nervous system: a study from the Republic of Srpska, Bosnia & Herzegovina. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 177-186.	1.9	12
39	Outpatient utilization of antibiotics in the Republic of Srpska, in 2007 and 2008. <i>Scripta Medica</i> , 2010, 41, 22-28.	0.1	1
40	Utilisation of cardiovascular medicines in Republic of Srpska, Bosnia and Herzegovina, 5 years study. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 320-326.	1.9	11
41	Pharmacoepidemiological analysis of use of medicines prescribed on the account of the Republic of Srpska health insurance fund in the period of 2003-2004. <i>Scripta Medica</i> , 2005, 36, 25-35.	0.1	0
42	Trends in Antihypertensive Medicine Utilization in the Republic of Srpska, Bosnia and Herzegovina: An Eleven-Year Follow-Up. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
43	Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	7